Is linezolid available as oral tablets and an injectable solution?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Linezolid Formulation Availability

Yes, linezolid is available in both oral tablet and intravenous (IV) injection formulations, with 100% bioavailability allowing interchangeable use without dose adjustment. 1, 2

Available Formulations

Linezolid comes in three distinct formulations:

  • Oral tablets (600 mg film-coated tablets)
  • Intravenous injection (for IV infusion)
  • Oral suspension (also available but less commonly used)

1, 2

Key Clinical Advantage: Bioequivalence

The oral and IV formulations are bioequivalent with approximately 100% absolute bioavailability, meaning you can switch between routes without changing the dose 1, 2. This is explicitly stated in the FDA labeling: "linezolid may be given orally or intravenously without dose adjustment" 1.

Pharmacokinetic Equivalence

The FDA drug label demonstrates comparable pharmacokinetic parameters between formulations 1:

  • 600 mg oral tablet: Cmax 12.7 µg/mL, AUC 91.4 µg·h/mL
  • 600 mg IV injection: Cmax 12.9 µg/mL, AUC 80.2 µg·h/mL

Maximum plasma concentrations are reached at 1-2 hours for oral dosing versus 0.5 hours for IV administration, but total drug exposure remains equivalent 1, 2.

Standard Dosing Across Formulations

The IDSA guidelines consistently list linezolid dosing as "600 mg PO/IV BID" for adults across multiple serious infections including 3:

  • Osteomyelitis
  • Septic arthritis
  • Meningitis
  • Brain abscess
  • Complicated skin and soft tissue infections

This "PO/IV" notation throughout the guidelines confirms both routes are clinically acceptable and interchangeable.

Clinical Implications

The ability to use oral linezolid instead of IV vancomycin offers significant practical advantages, including reduced hospital length of stay and elimination of IV access complications 4, 5. In propensity-matched patients with MRSA skin infections, oral linezolid achieved superior clinical success compared to IV vancomycin (odds ratio 4.0,95% CI 1.3-12.0) 4.

Food does not significantly affect absorption - while high-fat meals delay Tmax slightly and reduce Cmax by 17%, total AUC remains similar, so linezolid can be administered without regard to meals 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.